Review Article

The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies

Amy B. Heimberger

Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston TX 77030-4009, USA

E-mail: *Amy B. Heimberger - aheimber@mdanderson.org
*Corresponding author

Received: 7 June 11 Accepted: 10 October 11 Published: 14 November 11

This article may be cited as:
Heimberger AB. The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies. Surg Neurol Int 2011;2:163.
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2011/2/1/163/89886

Copyright: © 2011 Heimberger AB. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: High-grade primary and metastatic central nervous system (CNS) tumors are common, deadly, and refractory to conventional therapy and continue to be therapeutically challenging. A key nodal transcriptional factor, the signal transducer and activator of transcription 3 (STAT3), drives the fundamental components of tumor malignancy and metastases in the CNS by enhancing proliferation, angiogenesis, invasion, metastasis, and immunosuppression. The introduction of STAT3 inhibitors in clinical trials for this patient population is imminent.

Methods: STAT3 inhibitors have been extensively tested in a variety of preclinical murine models.

Results: The STAT3 inhibitor, WP1066, has displayed marked efficacy with minimal toxicity against malignancy in murine models, including established intracerebral tumors. The mechanism of this in vivo efficacy of the STAT3 blockade agents is a combination of direct tumor cytotoxicity and immune cytotoxic clearance.

Conclusions: Given their direct antitumor cytotoxic effects, STAT3 inhibitors may exert therapeutic activity in the monotherapy setting but may also have compelling use as immunotherapeutic modulators or as a salvage therapy.

Key Words: Central nervous system, cytotoxic agent, glioma, immunotherapy, metastasis, signal transducer and activator of transcription 3

INTRODUCTION

The median survival time for patients for patients with the more malignant types of gliomas such as glioblastoma multiforme (GBM) is still a dismal 15 months despite multimodality therapy, including temozolomide (TMZ).\textsuperscript{[58]} The prognosis is even worse for patients with brain metastasis from cancers such as melanoma, whose median survival time remains at 5 months.\textsuperscript{[50]} Metastatic tumors are among the most common brain tumors, and in the United States there are an estimated 150,000 cases per year. Disease metastatic to the central nervous system (CNS) accounts for 20% of cancer deaths annually, a rate that can be traced to an increase in the median survival time of patients with cancer because of modern therapies, increased availability of advanced imaging techniques for early detection, and vigilant surveillance protocols for monitoring recurrence. Additionally, most systemic
treatments (i.e., chemotherapeutic agents, which may penetrate the brain poorly) can transiently weaken the blood–brain barrier (BBB) and allow systemic disease to be seeded in the CNS, leaving the brain a safe haven for tumor growth. Most of these patients with brain metastases are excluded from clinical trials owing to their poor prognosis. We are seeing an increased incidence of brain metastasis secondary to the increasing longevity of these patients. There is clearly an unmet clinical need to develop therapeutic strategies that exert efficacy against CNS malignancies. Only now are pharmaceutical companies coming to the realization that there is a great untapped market for these agents, but few developmental chemists and translational researchers have considered CNS activity when developing drugs.

The signal transducer and activator of transcription 3 (STAT3) pathway is a potent regulator of tumorigenesis, tumor-mediated immune suppression, and metastasis to the brain. A variety of growth factors and cytokines activate STAT3 by phosphorylating the tyrosine residue in the STAT3 transactivation domain. Phosphorylated STAT3 (p-STAT3) then translocates into the nucleus and induces the expression of a wide variety of target genes involved in tumorigenesis. STAT3 is overexpressed almost ubiquitously in malignancies, including gliomas, and propagates tumorigenesis by preventing apoptosis and enhancing proliferation, angiogenesis, invasiveness, and metastasis. The STAT3 pathway becomes constitutively active in diverse tumor-infiltrating immune cells, markedly impairing their antitumor effector responses and enhancing the functional activity of immunosuppressive regulatory T cells (Tregs). Glial cancer stem cells (gCSCs) are also dependent on the STAT3 pathway, including for their immunosuppressive properties. Targeting a molecular hub of both tumor-mediated immune suppression and tumorigenesis is a highly novel therapeutic strategy.

To target this pathway, several novel inhibitors of the STAT3 pathway have been designed and synthesized that show marked activity against intracerebral tumors in vivo both by directly interfering with tumorigenicity and by reversing tumor-mediated immune suppression. Our data demonstrate the highly promising potential application of one of these, WP1066, which we have been extensively developing. We hypothesize that by targeting multifactorial signaling mediated by the STAT3 pathway and reversing immunosuppression, we can improve survival in patients with gliomas and brain metastasis—a typically underserved patient population that continues to have a dismal survival prospect.

**BACKGROUND**

STAT3 is a key transcription factor that drives the fundamental components of malignancy and metastasis including those in gliomas. In many tumors, STAT3 is constitutively active including the unphosphorylated form which is also capable of inducing oncoproteins. GBM tumors and glioma cell lines have been shown to have high levels of both in comparison to normal brain tissue. We have shown that STAT3 is overexpressed in most gliomas and is a negative prognostic marker for survival in patients who have malignant glioma. STAT3 has also been shown to be a master regulator for mesenchymal transformation in brain tumors. The STAT3 pathway is also either likely to be or is actually overexpressed in other types of more benign CNS tumors, such as choroid plexus papilloma, ependymoma, and meningioma. STAT3 has also been shown to be crucial to tumorigenesis and a mediator of poor prognosis in a wide variety of other malignancies, such as gastric and colon cancers, renal cancer, ovarian cancer, squamous cell cancer, hepatocellular carcinoma, and anaplastic large cell lymphoma. A study by Xie et al. confirmed the importance of STAT3 in melanoma metastasis by showing that only highly metastatic melanoma cell lines, but not poorly metastatic ones, have elevated levels of activated STAT3 (p-STAT3). Furthermore, blockade of activated STAT3 prevents the invasiveness of melanoma cells, inhibits tumor growth, and prevents metastasis, suggesting that STAT3 activation is the crucial event in melanoma metastasis. Subsequent tissue microarray studies of brain metastasis in human melanoma patients have demonstrated higher levels of expression of activated STAT3 in melanoma brain metastasis specimens compared with those from parenchymal tumors. Thus, this ubiquitous pathway is upregulated in almost all malignancies studied thus far, especially within CNS tumors.

STAT3 has also been implicated as a key regulator of immunosuppression in patients with cancer, and is therefore considered a potential target for immunotherapy. The p-STAT3 pathway is induced in the immune cells within the tumor microenvironment, which downregulates their antitumor immune responses. Specifically, p-STAT3 has been shown to suppress macrophage activation and to limit their inflammatory responses, reduce natural killer (NK) cell and neutrophil cellular cytotoxicity, and reduce the expression of major histocompatibility complex (MHC) II, CD50, CD56, and interleukin (IL)-12 in dendritic cells, rendering them unable to stimulate T cells and to generate effective antitumor immunity. STAT3 activation enhances the suppressive activities of human Tregs by upregulating FoxP3 expression. Tumor-associated macrophages (MΦ)/microglia have been shown to become polarized via the STAT3 pathway toward immunosuppressive and tumor supportive phenotypes (M2) that then contribute to angiogenesis and tumor invasion. Cumulatively, these data indicate that STAT3 is a key pathway that prevents
the immune system from recognizing and eliminating malignancy from our bodies.

Finally, the p-STAT3 pathway is a fundamental hub for the control of gCSCs, which are undifferentiated cells with the capacity for self-renewal and a high proliferative potential. The gCSCs confer the resistance to chemotherapy and radiation that is observed in cancer patients. Many investigators believe that without targeting this subpopulation of cells therapeutically, tumors will continue to persist and recur. Implantation of gCSCs in mice recapitulates the key characteristics of human malignancies. The gCSCs frequently have overexpression of p-STAT3, which results in proliferation and tumorigenic potential. We have also shown that the gCSCs are highly immunosuppressive, and when we block STAT3 in the gCSCs with WP1066, there is nearly complete reversal of tumor-mediated immune suppression. The use of p-STAT3 inhibitors to overcome tumor-mediated immune suppression may result in the ability of the immune system to recognize and eradicate the tumor, which the tumor typically prevents it from doing. Cumulatively, these data indicate that targeting the STAT3 pathway is a multipronged approach that is truly unique.

RESULTS AND DISCUSSION

WP1066 is an analogue of caffeic acid that is a very potent and specific inhibitor of p-STAT3. It has been shown to induce apoptosis in gliomas by downregulating the antiapoptotic proteins Mcl-1, Bel-X, and c-Myc, while activating Bax. In other types of solid malignancy, WP1066 has been shown to inhibit vascular endothelial growth factor (VEGF) production by the tumor and associated in vivo angiogenesis, indicating that inhibition of STAT3 results in a multiplicity of antitumor mechanisms. When WP1066 was administered to mice orally, toxicity was minimal. Detailed histological examination of the spleen, kidney, lung, heart, and bone marrow demonstrated no significant abnormalities in mice given the 40-mg/kg dose by oral gavage. Because WP1066 is a potent immune activator, nonspecific immune reactivity in the CNS remains a consideration; however, Luxol fast blue staining of the CNS failed to demonstrate any evidence of CNS autoimmunity. Thus, preliminary toxicity has demonstrated that WP1066 has an extremely desirable profile.

Bioavailability studies after oral administration yielded mean peak plasma concentrations greater than 2 μM. Furthermore, kinetic data indicate that WP1066 has a marked ability to achieve excellent CNS penetration, exceeding 30 μM concentrations within the CNS of mice with an intact BBB, and the brain drug levels were long lasting (weeks). These doses markedly exceed the direct antitumor effects on cancer stem cells and tumor-mediated immune suppression.

Other studies have demonstrated statistically significant suppression of tumor growth in mice with head and neck carcinoma, pancreatic cancer, bladder cancer, glioma, B-cell non-Hodgkin’s lymphoma and myeloma, and chronic myelogenous leukemia, when given WP1066. Treatment of established tumors in vivo with WP1066 has resulted in decreased tumor proliferation, tumor volume, and angiogenesis/vascular proliferation. To determine whether treatment with WP1066 is efficacious against intracerebral tumors established in mice, the mice were treated with WP1066. Median survival durations and rates were markedly enhanced when WP1066 was administered, and 80% of WP1066-treated animals survived long term compared with 0% of control mice treated with the injection vehicle control (P = 0.0076). Similar results have been seen in other animal model systems of intracranial gliomas.

Specifically, using the RCAS/Ntv-a system, mice were engineered to coexpress platelet-derived growth factor receptor (PDGF)-B + B-cell lymphoma (Bcl)-2 under the control of the glioneuronal-specific Nestin promoter. In mice expressing both PDGF-B + Bcl-2 that were treated with WP1066, there was a 55.5% increase in median survival time (P < 0.01), with an associated inhibition of intratumoral p-STAT3 and macrophages. These data demonstrate the compelling efficacy of WP1066 against established tumors in the CNS in multiple murine models.

In addition to the ability of WP1066 to enhance immune-mediated antitumor immune responses, it also markedly inhibited Tregs in vivo. We have also shown that WP1066 can upregulate costimulatory molecules (CD80, CD86) on ex vivo human microglia isolated from glioma patients, induce proinflammatory cytokine secretion essential for T effector responses, and induce impaired T cells to become activated and proliferate, indicating that STAT3 blockade is a potent approach for modulating immunosuppression. Other investigators have shown that by ablating STAT3 in the hematopoietic cells in mice, there was marked enhancement of function within T cells, NK cells, and dendritic cells in tumor-bearing mice. This ablation of STAT3 in only the hematopoietic cells resulted in marked antitumor effects in vivo, indicating that STAT3 expression within the immune cells is what restrains the antitumor immune eradication.

This indicates that WP1066 could also be developed as an immunotherapeutic for malignancies. Finally, we have shown that WP1066 can target glioma cancer stem cells that are responsible for therapeutic resistance.

There are several other STAT3 inhibitory compounds that have therapeutic potential for introduction into clinical trials for patients with CNS malignancies [Table 1]. JSI-124 (cucurbitacin I) has demonstrated prolonged...
Because the p-STAT3 agents inhibit in vitro activity against lymphomas and cervical cancer and in vivo growth inhibition of human breast carcinoma and syngeneic murine melanoma, but not in carcinomas that lack constitutive expression of p-STAT3. 

In an in vivo sarcoma model in which JSI-124 had minimal direct tumor cytotoxicity, JSI-124 enhanced dendritic cell vaccination, resulting in marked tumor suppression that persisted for more than 4 weeks. Furthermore, JSI-124 in vivo promoted a Th1 (cytotoxic effector) phenotype and enhanced the levels of glioma-infiltrating immune cells. Immune-competent mice with intracerebral tumors treated with JSI-124 had prolonged survival, but this efficacy was not observed in an immune-incompetent background, indicating that the immune system played a role in the in vivo effect of JSI-124 in a manner similar to WP1066. Furthermore, when JSI-124 was combined with adoptive transfer of type I cytotoxic T lymphocytes, survival was further enhanced compared with treatment with either modality alone. The authors concluded that the inhibition of STAT3 could reverse the immunosuppressive immune microenvironment and promote the efficacy of adoptive transfer therapy. 

Finally, although described as an inhibitor of janus kinase 2 (Jak2, which is upstream of STAT3), AZD1480 also possesses serious clinical potential for the treatment of patients with CNS malignancies. AZD1480 has demonstrated significant growth inhibition on a wide variety of human solid tumor xenografts and myeloproliferative neoplasms and is already in phase I clinical trials. Thus, there are several serious contenders that can block STAT3, which are likely to be introduced into clinical trials for patients with gliomas within the next few years.

### Table 1: Signal transducer and activator of transcription 3 inhibitors with therapeutic potential for central nervous system malignancies

| Agent | Typical in vivo dose | Route of administration | Mode of action | Target cells | Clinical trial stage |
|-------|----------------------|-------------------------|----------------|--------------|---------------------|
| WP1066 | 40 mg/kg on Monday, Wednesday and Friday | Oral, IV, IP | Selective inhibitor p-STAT3/ inhibition of STAT3 nuclear translocation | Glioma, melanoma, head and neck carcinoma, pancreatic cancer, bladder cancer, renal cell, non-small cell lung, B-cell non-Hodgkin’s lymphoma and myeloma, chronic myelogenous leukemia | Preclinical development/IND pending |
| JSI-124 | 1 ng/g/day | IP | Selective inhibitor of JAK/STAT3 | Glioma, melanoma, lymphoma, cervical cancer, breast | Preclinical |

**STAT3:** Signal transducer and activator of transcription 3

### CURRENT AND FUTURE DEVELOPMENTS

The potential for using p-STAT3 inhibitors in the treatment of a variety of cancers, including CNS metastasis, is evident. After successful completion of phase I testing, an interesting application of these compounds will be in combination with other immunotherapeutic strategies. For example, p-STAT3 inhibitors could be used in combination with dendritic cell vaccinations. Alternatively, in the treatment of high-grade malignant gliomas, we have previously shown that a peptide vaccine (PEP-3-KLH/CDX-110) directed to the splice junction of type III variant of the epidermal growth factor receptor (EGFRvIII) is effective in the treatment of intracerebral tumors in both murine models and human patients who have newly diagnosed GBM. The trials were limited to GBM patients who underwent gross-total resections so that the immunosuppressive properties of the tumor were negated as much as possible. However, many GBM patients cannot have a surgical resection that places their disease in a microscopic residual infiltrative state, and therefore, agents that can counteract the immunosuppressive influence of a bulky tumor are essential. Within malignant glioma patients, there is a prominent Treg population in the systemic circulation and marked infiltration within the tumors in the CNS. These Tregs remain elevated even in patients receiving PEP-3-KLH. Because the p-STAT3 agents inhibit Tregs, enhance cytotoxic responses, and reverse immune suppression, they have the potential to further enhance peptide-based vaccination strategies, such as with the PEP-3-KLH/CDX-110 vaccine, possibly including patients with bulky tumors who are unable to undergo surgical resection.
leading to a more hypoxic environment.\textsuperscript{[20]} Moreover, we have recently demonstrated that hypoxia can induce the expression of p-STAT3.\textsuperscript{[16]} Thus, it is possible that the failure of anti-VEGF strategies may be associated with upregulation of STAT3. If this is the case, then agents targeting the STAT3 pathway given in combination with anti-VEGF therapeutics may prevent or delay tumor recurrence and/or may be an appropriate salvage therapy.\textsuperscript{[27]}

In summary, STAT3 blockade agents have multiple mechanisms of activity, including direct tumor cytotoxic effects and the ability to overcome the negative modulatory effects of the local tumor microenvironment, allowing for immunological recognition and clearance of cancer cells. The targets of STAT3 blockade agents are not only the STAT3 in tumor cells, but also the STAT3 in immune cells, which use the p-STAT3 pathway to prevent antitumor immune reactivity. The preclinical data thus far available are sufficiently compelling to justify the consideration of human clinical trials to test these agents. The small molecule inhibitors of p-STAT3 can be used to treat a wide variety of cancers but, in particular, may have a meaningful impact on patients with primary and metastatic tumors of the CNS, a markedly underserved patient population.

REFERENCES

1. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008;14:2828-35.
2. Bao JJ, Jokt I, Szymanski S, Priebe W. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in prostate cancer cells. Clin Cancer Res 2005;11:9026-75.
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cell lines promote radioreistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
4. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72.
5. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
6. Carro MS, Lim WK, Alvarez MJ, Bollito RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal reprogramming of brain tumors. Nature 2010;463:318-25.
7. Cattaneo E, Magrassi L, De-Fraja C, Conti L, Di Gennaro I, Di Gennaro I, et al. Variations in the levels of the JAK/STAT and Shc proteins in human brain tumors. Anticancer Res 1998;18:3381-7.
8. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, et al, editors. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. 98th American Association of Cancer Research Annual Meeting; Los Angeles, CA: 2007.
9. Chen CL, Hsieh FC, Lieblin JC, Brown J, Chan C, Wallace JA, et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007;96:591-9.
10. Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, et al. Effect of a small molecule inhibitor of the Jak2/STAT3 pathway on self-renewal of glioblastoma stem cells. J Clin Oncol 2008;26:899s.

http://www.surgicalneurologyint.com/content/2/1/163

11. Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Int J Oncol 2011;38:555-69.
12. Fecci PE, Mitchell DA, Whitesides JE, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302.
13. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-I CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008;180:2089-98.
14. Gong W, Wang L, Yao J, Jain A, Wei D, Aldape K, et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenenic phenotype of human gastric cancer. Clin Cancer Res 2005;11:1386-93.
15. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, et al. WP1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. 98th American Association of Cancer Research Annual Meeting; Los Angeles, CA: 2007.
16. Hedvat M, Huszar D, Herrmann A, Gogzit JM, Schroeder A, Sheehy A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97.
17. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al. Incidence and prognostic impact of FocP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008;14:5166-72.
18. Heimberger AB, Croży LE, Archer GE, Hess KR, Wikström CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9:4247-54.
19. Hong H, Aoyama T, Kuroda K, Sato A, Asakuma S, Ito K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9.
20. Hong H, Aoyama T, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: A study of incidence and its association with pathological features and clinical outcome. J Urology 2002;168:762-5.
21. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: Clinical implications. Clin Cancer Res 2007;13:1362-6.
22. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-6.
23. Ioannidis S, Lamb ML, Wang T, Almeida L, Block MH, Davies AM, et al. Discovery of S-Chloro-N(2)-(|-(15S)-1-(5-fluoropyrimidin-2-yl)ethyl)-N(4)-(S-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway. J Med Chem 2011;54:262-76.
24. Iwamura A, Szymanski S, Ishida E, Aoki H, Yotokawa T, Fokt I, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44.
25. Johnson MD, O’Connell M, Vito F, Bakos RS. Increased STAT3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt- mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol 2009;92:129-36.
26. Keenan O, Johannsson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54.
27. Khoury JD, Medeiros LJ, Rassidakis G, Yared MA, Ioannides S, Tsirlis P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in gliomas. Clin Cancer Res 2008;14:5166-72.
28. Khoury JD, Medeiros LJ, Rassidakis G, Yared MA, Ioannides S, Tsirlis P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in gliomas. Clin Cancer Res 2008;14:5166-72.
29. Kim LY, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-6.
30. Keenan O, Johannsson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54.
31. Khoury JD, Medeiros LJ, Rassidakis G, Yared MA, Tsirlis P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in gliomas. Clin Cancer Res 2008;14:5166-72.
32. Kim LY, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-6.
phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009;58:1023-32.

31. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, et al. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010;16:5722-33.

32. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Platon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicompartment anti-tumor immunity. Nat Med 2005;11:1314-21.

33. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dalak-Yazici Y, Zhao M, et al. Therapeutic suppression of constitutive and inducible JAK/STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 2009;8:117-27.

34. Kupferman ME, Zhou G, Zhao M, Jasser S, Dalak-Yazici Y, Priebe W, et al. A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. 97th American Association of Cancer Research Annual Meeting; Washington, DC: 2006.

35. Lin EY, Li JF, Gnatovsky L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46.

36. Madden T, Kazeroori R, Myer J, Culotta K, Donato N, Johansen M, et al. The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway. 97th Annual Meeting of the American Association for Cancer Research; Washington, DC: 2006.

37. Masuda M, Suzui M, Yasumatu R. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-5.

38. McLoughlin RM, Jenkins BJ, Grail D, Williams A, Fielding C, Parker CR, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005;102:9589-94.

39. Merino B, Diez-Fernandez C, Ruiz-Gayo M, Somozo B. Choroid plexus epithelial cells co-express the long and short form of the leptin receptor. Neurosci Lett 2006;393:269-72.

40. Murat A, Migliavacca E, Gorla T, Lambiw VL, Shy T, Hamou MF, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-24.

41. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005;175:4338-46.

42. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DJ. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-35.

43. Nussbaum ES, Djillian HR, Cho KH, Halla WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-8.

44. O’Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and independent pathways. EMBO J 1998;17:1006-18.

45. Priebe W, Fokt I, Szymanski S, Madden T, Bao JI, Lesyng B, et al. Design, synthesis and structure-activity relationships of novel Jak2/STAT3 signaling inhibitors. 97th Annual Meeting of the American Association for Cancer Research 2006;67:LB-298.

46. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002;21:8404-13.

47. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-I inhibition. Mol Cancer Ther 2009;8:1867-77.

48. Samanta A, Kantarjian H, Priebe W, Airlingham R, editors. Cross talk between Jak2 and Lyn in Bcr-Abl signaling pathway in cells from Imatinib-sensitive and resistant chronic myelogenous leukemia (CML). 98th American Association of Cancer Research Annual Meeting; Los Angeles, CA: 2007.

49. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRVIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-33.

50. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88:11-20.

51. Sampson JH, Heinberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.

52. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353:811-22.

53. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011;25:538-50.

54. Sebti SM, Jove R. Inhibitors: None, assignee. Materials and methods for treatment of cancer and identification of anti-cancer compounds. US2004 .

55. Shah NG, Trivedi TD, Tankshali RA. STAT3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006;21:175-83.

56. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27:2383-92.

57. Shi X, Franko B, Frantz C, Amin HM, Lai R, JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signaling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma. Br J Haematol 2006;135:26-32.

58. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-98.

59. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010;9:67-78.

60. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLOS One 2011;6:e16195.

61. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010;12:1113-25.

62. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 2005;24:970-9.

63. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershwenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2010;70:67-78.

64. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23:3550-60.

65. Yang J, Chatterjee-Kishore M, Saguistis SM, Nguyen H, Schlessinger K, Levy DE, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.

66. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.

67. Yu H, Kortylewski M, Pardoll D. Crossover talk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.

68. Zorn E, Nelson EA, Mohseni M, Porchery F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT3-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.